Michigan State University researchers use AI and nanomedicine to identify blood-based biomarkers for prostate cancer and atherosclerosis.
Key Details
- 1Researchers from MSU, Augusta University, Karolinska Institute, and Stanford developed a new diagnostic platform.
- 2The method combines nanomedicine, AI, and causal analysis to identify rare plasma protein biomarkers.
- 3Initial targets were metastatic prostate cancer and atherosclerosis (clogged arteries).
- 4Published in the Chemical Engineering Journal on April 1, 2025.
- 5Funding from the American Heart Association, DoD Prostate Cancer Research, NIH, and NSF.
Why It Matters
Integrating radiology expertise with AI-driven biomarker discovery could transform early detection and precision medicine, providing radiologists with novel tools for non-invasive disease diagnosis. These advances support the radiology-AI community's efforts to enhance diagnostic accuracy and patient stratification.
Source
EurekAlert
Related News
•EurekAlert
AI Method Automates X-ray Absorption Spectroscopy for Material Analysis
Researchers have developed an AI-based approach to automate and enhance the analysis of X-ray absorption spectroscopy (XAS) data for materials science.
•EurekAlert
Zero-Cost EHR-Based AI Tool Scales Dementia Detection in Primary Care
A zero-cost, EHR-integrated AI tool significantly boosts dementia detection in primary care clinics without adding clinician workload.
•EurekAlert
BraDiPho: New 3D AI Atlas Integrates Brain Dissections with MRI
Researchers have developed BraDiPho, a tool that merges ex-vivo photogrammetric brain dissection data with in-vivo MRI tractography using AI.